Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Bolinder, Jan; Ljunggren, Östen; Kullberg, Joel; Johansson, Lars; Wilding, John; Maria Langkilde, Anna; Sugg, Jennifer; Parikh, Shamik

doi:10.1210/jc.2011-2260

Public

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Published in The Journal of Clinical Endocrinology & Metabolism • Jan 12, 2012

Authors:

Jan Bolinder

Östen Ljunggren

Joel Kullberg

Abstract

CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight ...

Subject

Dapagliflozin

Medicine

Metformin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!